| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a135a933620c99beab01d4ac785d25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9d18a3d6a06972242f4497e36ed709e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c90f4702549fb2dce6423ef9b3a96f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6eaf17873c8c694699ab8b9e5ae7956f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate |
2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78103a756299505507fe75e2981853c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cda50339fb2e1e73cc9f79c0461b2921
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac92d1b3496335548af9199a03c5c27c |
| publicationDate |
2014-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014080895-A1 |
| titleOfInvention |
Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| abstract |
The present invention provides a method for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Heat Shock Protein 90 (Hsp90) inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. The present invention also provides pharmaceutical compositions comprising an amount of an oligonucleotide which reduces clusterin expression, and a Hsp90 inhibitor for use in treating a mammalian subject affected by prostate cancer. Also provided are oligonucleotides which reduce clusterin expression for use in combination with a Hsp90 inhibitor in treating a mammalian subject affected by prostate cancer, and a composition for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Hsp90 inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017184956-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10927115-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10442806-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10112947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9074209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261187-B2 |
| priorityDate |
2011-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |